Tumor necrosis factor (TNF) signaling is mediated via two distinct receptors, TNFR2 and TNFR1, which shows partially overlapping signaling mechanisms and biological roles. In the present study, TNFR2 and TNFR1 signal transduction mechanisms involved in activation of NFκB and CMV promoter-enhancer were compared with respect to their susceptibility towards inhibitors of intracellular signaling. For this, we used SW480 cells, where we have shown that TNF-signaling can occur independently through each of the two receptors. The TNFR1 response was inhibited by D609, bromophenacyl bromide (BPB), nordihydroguararetic acid (NDGA), and by sodium salicylate, while TNFR2-mediated activation of NFκB and CMV promoter-enhancer was resistant to these compounds. The signaling mechanisms known to be affected by these inhibitors include phospholipases as well as redox-and pH-sensitive intracellular components. Our results imply that TNFR2 signaling involved in NFκB activation proceeds independently of these inhibitor-sensitive signaling components, indicating distinct signaling pathways not shared with TNFR1.
Introduction
The cytokine tumor necrosis factor (TNF) is a central mediator of inflammation, immune response and antiviral defence (Old, 1988) . TNF is a strong activator of transcription factor NFκB which is involved in transcriptional regulation of genes coding for immunoglobulin κ light chain, MHC antigens, cytokines, cytokine receptors and adhesion molecules, as well as in the activation of human immunodeficiency virus and cytomegalovirus (CMV) (Baeuerle and Henkel, 1994) . NFκB which is constitutively present in the cytoplasm, bound to NFκB inhibitor, IκB (Beg et al., 1993) , is activated posttranslationally by cellular signals that lead to proteasomal degradation of IκB (Palombella et al., 1994) after its phosphorylation by the IκB-kinase (IKK) complex (Karin and Ben-Neriah, 2000) . Elucidation of TNF activated signal transduction pathways leading to NFκB activation is a major challenge in trying to understand how TNF mediates cellular events involved in inflammation and immune responses.
TNF binds and signals through two distinct receptors, TNFR1 (CD120a) and TNFR2 (CD120b) which are both present on most cells (Tartaglia et al., 1991) . TNFR1 and TNFR2 are members of the TNF receptor superfamily characterized by cysteine-rich pseudorepeats in their extracellular regions (Beutler and van Huffel, 1994; Smith et al., 1994) . Activation of TNFR1 appears to be sufficient to induce most common TNF reponses like activation of NFκB, cytotoxicity and proliferation (Tartaglia et al., 1991; Schutze et al., 1992; Laegreid et al., 1994) . However, it has been demonstrated that in some cell types, TNFR2 can independently mediate cellular responses like activation of NFκB (Laegreid et al., 1994; Mukhopadhyay et al., 2001) , proliferation (Grell et al., 1998) and cell death (Heller et al., 1992; Medvedev et al., 1994; Grell et al., 1999; Baxter et al., 1999) . A number of studies even indicate that signaling through both receptors may be important for TNF responses like regulation of adhesion molecule expression, and cell death (Shalaby et al., 1990; Abe et al., 1993; Declercq et al., 1998; Grell et al., 1999) . Furthermore, TNFR1 and TNFR2 play distinct and specific roles in discriminating between the effects of TNF and the TNF related ligand lymphotoxin-α (Medvedev et al., 1996a; Medvedev et al., 1996b) . The diverse involvement of the two receptors in the large repertoire of cellular TNF responses, brings attention to the molecular mechanisms underlying intracellular events induced by each of TNFR1 and TNFR2, including cross-talks between these events.
TNF induced NFκB activation has been found to involve a number of intracellular proteins associated with the nonhomologous intracellular domains of TNFR1 and TNFR2. TNF receptor associated protein 2 (TRAF2), whose overexpression has been shown to activate NFκB (Rothe et al., 1995b) binds directly to TNFR2 (Rothe et al., 1994) . TRAF1 binds to TRAF2 (Rothe et al., 1994) and this heterocomplex in turn leads to recruitment of inhibitors of apoptotic protein (cIAP1) and/or cIAP2 (Rothe et al., 1995a) . It is now thought that mostly TRAF2 interacts with TNFR2 directly, with TRAF1 interacting indirectly and TRAF3 also able to associate. TRAF2 is recruited to TNFR1 indirectly throught a specific interaction with the protein TNF receptorassociated death domain protein (TRADD) (Hsu et al., 1995) that directly binds to TNFR1 throught its own death domain sequence (Hsu et al., 1995) . TRADD recruits the downstream signaling adaptor molecules Fas-associated death domain protein (FADD) and receptor-interacting protein (RIP). RIP, originally identified as a Fas-associating molecule (Stanger et al., 1995) , interacts with both TNFR1/TNFR2 Liu et al., 1996) . TNFR1-mediated NFκB activation has been reported to involve phosphatidylcholine specific phospholipase C (PC-PLC), sphingomyelinase (SMase), phospholipase A2 (Schutze et al., 1992; Yang et al., 1993; Thommesen et al., 1998) atypical PKCs (Anthonsen et al., 2001) and protein kinase C -ζ (PKC-ζ) activated by ceramide (Lozano et al., 1994; Folgueira et al., 1996) . TNFR2-mediated signaling is less studied even though a TNFR2 specific signaling component, the tyrosine kinase Etk/Bmx, has recently been identified to be involved in TNF-induced angiogenesis (Pan et al., 2002) . Activation of TNFR2 in some cells has been shown to be proliferative, but it is also known to have a function in regulating TNF-induced apoptosis (reviewed in (MacEwan, 2002) . Furthermore, TNFR2 signaling seems to play an important independent role in chronic inflammatory conditions like Crohns disease (Holtmann et al., 2002) . Opposite roles of TNFR1 and TNFR2 is reported. In retinal ischemia TNFR1 auguments neuronal death, while TNFR2 promotes neuroprotection, suggesting distinct biological roles (Fontaine et al., 2002) .
Our previous studies on TNFR2-and TNFR1-mediated activation of NFκB and CMV immediate early enhancer have indicated the excistence of both overlapping and independent signaling mechanisms (Laegreid et al., 1994; Laegreid et al., 1995) . In the present study we compared the effect of commonly used inhibitors on TNFR2 and TNFR1 mediated responses in SW480 cells. We found that TNFR1 mediated activation of transcription factor NFκB and CMV promoterenhancer is inhibited by a number of compounds to which the TNFR2 response was insensitive. The results indicate that TNFR2 mediated NFκB activation proceeds via signaling mechanisms distinctly different from those involved in TNFR1 induced NFκB activation.
Materials and Methods
Cells and reagents SW480/β-gal cells (generously provided by Dr. Gerald Ranges, Miles Inc., West Haven, CT, USA) contain a beta galactosidase (β-gal) reportergene under the control of the cytomegalovirus immediate early promoter-enhancer (CMV IE) (Galloway et al., 1992) . SW480/β-gal cells were grown in RPMI1640 (Gibco Laboratories, Paisley, Scotland), supplemented with 2 mM L-glutamine, 10% heat-inactivated FCS (HyClone, Logan, USA) and 40 µg/ml garamycin. Human recombinant TNF, with specific activity 7.6 × 10 7 U/mg protein, was generously supplied by Dr. Refaat Shalaby, Genentech Inc. (South San Francisco, USA). TNFR2 antiserum (p75 AS) was generated by multiple injections of a rabbit with recombinant soluble TNFR2 (Laegreid et al., 1994) . The generation and purification of the mAb htr-9 and utr-4 against TNFR1 and TNFR2 respectively, has been reported . Htr-9 and utr-4 was generously provided by Dr. M Brockhaus , Hoffmann La-Roche Ltd. (Basel, Switzerland). Biotinylation of htr-9 and utr-4 was performed as described (Updyke and Nicolson, 1984) . All mAbs were purified on a Sepharose goat anti-mouse IgG column (Zymed Laboratories Inc., South San Francisco, USA). Affinity purified antibodies against NFκB proteins p50, p65, p49, rel C and rel B, as well as antibodies against ISGF-3 p84/p91 were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, USA).
4-Bromophenacyl bromide (BPB) (32 mM), nordihydroguaiaretic acid (NDGA) (0,1 M), and PMA (1 mg/ml) (Sigma Chemical Company, St.Louis, USA), were dissolved in 96% ethanol. Tricycloedecan-9-yl-xanthogenate (D609) (10 mg/ml) (Kamyia Biomedical Company, Thousand Oaks, CA, USA) and sodium salicylate (1 M) (Sigma) was dissolved in medium without serum, benzamidine (Sigma) in 50% ethanol at 0.5 M, phenylmethylsulfonyl fluoride (PMSF) (Sigma) in isopropanol at 0.1 M, and pyrrolidine dithiocarbamate (PDTC) (Sigma) in PBS at 0,2 M. BPB and PDTC were always prepared fresh before use, while the other reagents were stable for some weeks (D609, PMSF, 4
Stimulation of cells Cells were seeded out in normal growth medium at 1 × 10 6 cells pr well in 6-well plates (for preparation of nuclear extracts) or at 2 × 10 4 in 96-well microtiter plates (for reportergene analysis) and cultivated for three days (postconfluent). After pretreatment with inhibitors for the indicated time periods, the stimulating agent was added and incubation was continued in the presence of inhibitors. D609 was found to loose activity in the presence of 10% FCS, therefore all experiments with inhibitors (pretreatment and stimulation) were performed in medium with 2% FCS.
Quantitative band shift assays and supershift analysis Preparation of nuclear extracts, native polyacrylamide gelelectrophoresis with [ 3 2 P]-labelled NFκB oligonucleotide probe (Promega Corporation, Madison, USA) and quantitation with a PhosphoImager (Molecular Dynamics, Sunnyvale, USA) was carried out as described (Laegreid et al., 1995) . Radioactivity counts were termed «PhosphoImager units» and were used to compare the relative amounts of radioactivity in bands within the same gel. Bandshift assays with [ 3 2 P] labeled OCT oligonucleotide (Promega) (5'-TGTCGAATGCA AATCACTAGAA-3') were performed in order to control that a similar amount of nuclear proteins was applied for each sample. All samples were analysed in at least two bandshift assays. For supershift analysis, nuclear extracts were first incubated with [ P] labeled NFκB probe in binding buffer (with poly(dI)(dC)) for 15 min. at room temperature. Then, 2 mg of antibody was added and incubation was continued for 1 h on ice before native polyacrylamide gelelectrophoresis.
Beta-galactosidase assay The β-galactosidase assay was performed essentially as described previously (Galloway et al., 1992) . Conversion of the substrate clorophenol-red D-galactopiranozide (CPRG, Boehringer Mannheim, Mannheim, Germany) was measured as optical density (OD) at 570 nm.
Flow cytometric analysis of TNFR mAb Cells were labeled with 10 µg/ml of biotinylated htr-9 or biotinylated utr-4 and 0.2 µg / ml streptavidin-phycoerythrin (Becton Dickinson, Mountain View, USA) as previously described (Shalaby et al., 1990) . Background fluorescence was estimated by adding 0.2 µg/ml streptavidinphycoerythrin/FITC-goat anti-murine Ig (Becton Dikinson). After washing three times in PBS-A + buffer, cells were analysed in a FACScan flow cytometer (Becton Dickinson).
Results
TNFR2 mediated activation of CMV promoter-enhancer and NFκB is resistant to D609 and BPB, while the TNFR1-and PMA responses are inhibited TNFR1 and TNFR2 signal transduction mechanisms have mostly been studied separately, in different cell lines. We have shown that SW480 adenocarcinoma cells provide a good model system for the comparison of TNFR2 and TNFR1 signal transduction (Laegreid et al., 1994; Laegreid et al., 1995; Medvedev et al., 1996a; Medvedev et al., 1996b) , since in this cell line, both receptors are endogenously expressed and can be specifically and selectively activated by agonistic TNFR1 or TNFR2 antibodies (Laegreid et al., 1994) .
In order to further characterize the differences between TNFR1 and TNFR2 signal transduction pathways, SW480/β-gal cells were stimulated with agonistic TNFR1 mAb htr-9 or with agonistic TNFR2 rabbit antiserum p75 AS in the presence of inhibitors of intracellular signal transduction components. The cellular response was measured as activation of transcription factor NFκB in band shift assays, or as activation of the CMV IE promoter-enhancer in a β-galactosidase reportergene assay. TNFR1-and TNF-mediated increase in β-galactosidase activity was inhibited in cells stimulated in presence of the xantate D609, an inhibitor of phospholipase C (PLC) (MullerDecker, 1989; Schutze et al., 1992) (Fig. 1A) . D609 also suppressed PMA mediated activation of the CMV promoterenhancer (Fig. 1C) . Inhibition of the TNFR1-and PMAresponses is evident at 6.25 mg D609/ml, but is most pronounced at 12.5 and 25 mg D609/ml. Interestingly, the TNFR2 response was not affected by D609 (Fig. 1B) , indicating that TNFR2 mediated activation of the CMV promoter-enhancer does not depend on components sensitive to this compound. Bandshift analysis of nuclear extracts from cells treated with TNF or with agonistic TNFR antibodies in the presence of D609, showed that D609 strongly inhibited TNFR1-and TNF-mediated activation of NFκB (Fig. 1D &  E) . TNFR2 mediated activation of NFκB was unaffected or enhanced by D609 (Fig. 1D & F) . Although D609 by itself weakly activated the CMV promoter-enhancer (Fig. 1A) , it was not found to induce activation of NFκB (data not shown).
Similar to D609, the alkylating agent 4-bromophenacyl bromide (BPB), which inhibits both type PLA2 and PLC phospholipases (Martin et al., 1987) , suppressed TNFR1-, TNF-as well as PMA-responses in the SW480 β-gal reportergene assay ( Fig. 2A & 2C) , while TNFR2 mediated activation of the CMV promoter-enhancer was insensitive to BPB (Fig. 2B) .
TNFR2-and PMA-mediated activation of CMV promoterenhancer and NFκB is resistant to NDGA and sodium salicylate, while the TNFR1-response is inhibited The antioxidant nordihydroguaiaretic acid (NDGA) (Niki, 1987) inhibits a variety of reactions dependent on oxidative processes, like lipoxygenase mediated generation of arachidonic acid metabolites (Miyazawa et al., 1985) and cytochrome P-450 catalysed electron transfer (Montag et al., 1993) . NDGA inhibited TNFR1-and TNF-induced activation of the CMV promoter-enhancer (Fig. 3A) , while the TNFR2 response was not affected (Fig. 3B) . Similarly, the PMA response was insensitive to NDGA (Fig. 3C) . In the present study, NDGA also strongly inhibited TNFR1-and TNF-mediated activation of NFκB. The inhibitiory effect was evident at 2 µM (approx. 30%), but was further increased at 10 mM (50-70% inhibition) ( Fig. 3D & E) . TNFR2 mediated activation of NFκB was insensitive to NDGA up to 2 mM, while a weak inhibition (less than 20%) was noted at 10 mM. (Fig. 3D & F) .
The anti-inflammatory agent sodium salicylate is also known as an antioxidant (Sagone and Husney, 1987) and inhibitor of cyclooxygenases (Vane and Botting, 1995) . This compound caused a weak, but highly reproducible suppression of TNFR1-and TNF-mediated CMV promoter-enhancer activation (Fig. 4A) , while the TNFR2-and PMA responses were not inhibited ( Fig. 4B and 4C ).
TNFR1 cell surface expression is not reduced by inhibitor treatment One possible mechanism underlying the observed selective inhibition of TNFR1 mediated responses could be downregulation of this receptor. Therefore, we performed flow cytometric analyses of cell surface TNFR expression in SW480/β-gal cells treated with inhibitors. We found that TNFR1 expression was not significantly changed in cells treated with D609 (12.5 µg/ml) or NDGA (4 µM) (Fig. 5) . NDGA did not change TNFR1 expression even at 10 µM 1 )
. TNFR1 levels were unaffected by treatment with sodium salicylate (1 h; 10 mM) and upregulated by BPB (1 h; 16 µM)
)
. Thus, it is unlikely that inhibition of the TNFR1 response is due to a decrease in TNFR1 cell surface levels. TNFR2 expression was either unaffected or slightly reduced by all inhibitors analysed ( Fig. 5 ; data not shown). However, even though they caused a weak reduction in TNFR2 cell surface levels, compounds like D609 or NDGA did not inhibit TNFR2 mediated responses ( Fig. 1 and 3) . Thus, the observed effects of the inhibitors are not a consequence of their effect on TNF receptor surface expression. This suggests that the inhibitors, at the concentrations employed in the present study, act at intracellular sites.
TNFR2 and TNFR1 mediate activation of NFκB complexes with similar subunit composition In order to examine whether the differences in TNFR2 and TNFR1 signaling mechanisms may manifest themselves in the activation of different subsets of rel protein hetero-and homodimers, we performed supershift analyses of TNFR2-and TNFR1-activated proteins binding to the NFκB consensus sequence. Two NFκB specific bandshifts of which the slower migrating complex is most strongly upregulated, are detected in nuclear h with D609 and stimulated with TNF (10 ng/ml; ○), TNFR1 mAb htr-9 (10 µg/ml; •), TNFR2 antiserum p75AS (diluted 1 : 100; ■ ) or PMA (5 ng/ml; □), or kept in medium alone (× ). Activation of the CMV promoter-enhancer was measured as β-galactosidase activity after stimulation for 4 h with TNF or htr-9 (A), p75 AS (B), or PMA (C). NFκB and OCT bandshift gel analysis (D) was performed after 1h stimulation. Quantitation of specific NFκB bandshifts is shown for TNF (○) or htr-9 (•) treated cells (E) and for p75AS (■) treated cells (F). The results shown are representative of four independent experiments.
data not shown.
extracts from stimulated SW480/β-gal cells (Laegreid et al., 1994) . Supershifts of NFκB bandshifts were produced by antisera against NFκB p50, NFκB p65 (relA), NFκB relC and NFκB relB (Fig. 6) . The faster migrating complex was recognized only by anti-p50, and thus most likely represents p50/p50 homodimers. Anti-p65 produced a strong supershift of the slower migrating complex, which was also recognized by anti-p50 (Fig. 6) , indicating that this complex mainly contains the p50/p65 heterodimer which is the most abundant NFκB factor in many cell types. In addition, the slower migrating complex represents hetero-and/or homodimers containing NFκB p65, rel C and rel B. Antibodies against the interferron-γ activated transcription factor ISGF-3 p84/p91 produced no change in bandshift mobilities (Fig. 7, lane 6) , indicating that the rel-supershifts are antigen-specific. No major differences were observed in the supershift patterns of nuclear extracts from cells stimulated via TNFR2 compared to extracts from cells stimulated with agonistic TNFR1 antibodies (Fig. 6) . Thus, although the two TNFR receptors employ different signaling pathways, they seem to activate similar subsets of rel protein hetero-and homodimers in SW480/β-gal cells. Fig. 4 . TNFR1-and TNFR2-mediated activation of the CMV promoter-enhancer in the presence of sodium salicylate. SW480/β-gal cells were pretreated for 1 h with sodium salicylate, followed by stimulation with TNF (○), TNFR1 mAb htr-9 (•), TNFR2 antiserum p75AS ( ■) or PMA ( □), or kept in medium alone ( ×) and measurement of β-galactosidase activity as indicated in Fig. 1 . The results shown are representative of four independent experiments. . Supershift analysis of NFκB proteins activated by TNFR1 and TNFR2. Nuclear ectracts from SW480/β-gal cells stimulated for 1h with either TNF (10 ng/ml), TNFR1 mAb htr-9 (10 µg/ml) or TNFR2 antiserum p75AS (dilution 1 : 100) were subjected to supershift analysis as described in Materials and methods. The bandshifts representing specific binding to the NFκB concensus sequence, as identified by competition with unlabeled oligonucleotides (Laegreid et al., 1994) are indicated by arrowheads.
Discussion
The cell line SW480/β-gal expresses both TNFR1 and TNFR2 receptor, which both independently activates NFκB and CMV promoter-enhancer. The TNFR2 signaling pathway is less studied and less well understood due to lack of receptor specific agonists. By use of TNFR2 antiserum p75 AS, however, we are able to specifically activate TNFR2 without affecting TNFR1, and hereby study the differences between these signaling pathways (Laegreid et al., 1994) .
In the present study we show that four different compounds, the phenolic plant lignan NDGA, the xantate D609, the alkylating agent bromophenacyl bromide (BPB) and antiinflammatory agent sodium salicylate, inhibit TNFR1-but not TNFR2-mediated activation of NFκB and CMV promoterenhancer. The differences in their chemical structure and activity suggest that these compounds do not affect the same signaling component. This is also confirmed by our finding that the PMA response in SW480/β-gal cells was inhibited by D609 and BPB, but not by NDGA or salicylate. Our observations in the human adenocarcinoma cell line SW480/ β-gal are compatible with reports from studies of several other cell types. Thus, TNFR1 mediated NFκB activation was found to be inhibited by NDGA in fibroblasts (SchulzeOsthoff et al., 1993) , by D609 in Jurkat cells and pre-B cells (Schutze et al., 1992; Wiegmann et al., 1994) and by sodium salicylate in Jurkat cells, endothelial cells and epithelial cells (Kopp and Ghosh, 1994; Pierce et al., 1996; Schwenger et al., 1998) . The resistance of TNFR2 mediated NFκB activation towards these inhibitors to our knowledge has not been previously reported. The present study indicates that the TNFR1 signaling mechanism leading to NFκB activation involves several distinct intracellular components which do not participate in the TNFR2 pathway.
The inhibitiory effect of D609 may indicate that PLC is involved in the signaling mechanism whereby TNFR1 activates NFκB in SW480/β-gal cells. This hypothesis is supported by the observation that the TNFR1 response is also reduced by BPB which, similarly to D609, can inhibit phospholipase C (PLC) (Martin et al., 1987) . However, secretory phospholipase A2 (sPLA2) is reported to be more potently inhibited by BPB than are type C phospholipases (Marshall et al., 1991) . Studies in our laboratory with more selective sPLA2 inhibitors strongly indicate that sPLA2 is involved in TNFR1 mediated NFκB activation in human keratinocytes (Thommesen et al., 1998) and recently a functional coupling between sPLA2 and cytosolic (c) PLA2 in TNF-mediated NFκB activation was reported (Anthonsen et al., 2001) . The effect of BPB in the present study may suggest that sPLA2 play a role in TNFR1 signaling, also in SW480/β-gal cells. BPB also has been reported to inhibit TNF-mediated NFκB activation in 293 embryonic cells (van Puijenbroek et al., 1999) .
Inhibition of TNFR1 mediated NFκB activation in SW480/ β-gal cells by antioxidants like NDGA and salicylate is in accordance with the observation that in some cell lines, redox signaling is involved in NFκB activation (Suzuki et al., 1997) . Alternatively, NDGA and salicylate, both being weak organic acids, may act through pH-sensitive intracellular components in the TNFR1 signaling pathway, as cytoplasmic acidification is proposed to be an important factor for the inhibitory effect of salicylate (Miyazawa et al., 1985) .
Salicylate has been reported to inhibit a variety of kinases (Jiang et al., 2003) , but does not inhibit TNFR2 responses measured in SW480 cells.
We have found that NDGA inhibits TNFR1-but not TNFR2-mediated NFκB activation also in the rhabdomyosarcoma cell line KYM-1 (unpublished results, Andrei Medvedev and Astrid Laegreid), which is another cell type where both TNF receptors can independently activate NFκB (Laegreid et al., 1994) . Interestingly, Grell et al found that TNFR1 mediated cytotoxicity in KYM-1 cells was insensitive to NDGA, while TNFR2 induced KYM-1 cytotoxicity was inhibited (Grell et al., 1999) . This indicates that the signaling mechanisms involved in the induction of cytotoxicity differ from those involved in activation of NFκB, both for TNFR1 and for TNFR2.
Given the known effects of the inhibitors used, it is possible that this TNFR1-specific pathway involves phospholipases like PLC and/or PLA2 as well as redox-or pH-sensitive intracellular components. This study suggests that TNFR2 contributes with more than a "ligand passing" role, as also shown for NFκB activation in HeLa and HEK 293cells (McFarlane et al., 2002) . Our study supports the view that TNFR2 independently can activate cellular responses and thus contributes with more than a ligand passing role, as also shown for NFκB activation of HeLa and HEK 293 cells (McFarlane et al., 2002) and for activation of the tyrosine kinase Etk/Bmx in angiogenesis (Pan et al., 2002) . Given the known effects of the inhibitors used, it is possible that the TNFR1 specific pathway involves phospholipases like PLC and/or PLA2 as well as redox-or pH-sensitive intracellular components. One may speculate that the TNFR1 specific pathway is linked to TRADD, since this TNFR-binding protein is not known to associate with TNFR2. It will be of interest to investigate a possible role of Etk/Bmx in TNFR2-mediated NFκB activation and to conduct futher studies to elucidate the biologial role of the TNFR2 signaling pathway.
